Preventive effect of rebamipide on N-methyl-N'-nitro-N-nitrosoguanidine-induced gastric carcinogenesis in rats. 2015

Hironobu Tsukamoto, and Tsutomu Mizoshita, and Takahito Katano, and Noriyuki Hayashi, and Keiji Ozeki, and Masahide Ebi, and Takaya Shimura, and Yoshinori Mori, and Satoshi Tanida, and Hiromi Kataoka, and Tetsuya Tsukamoto, and Masae Tatematsu, and Takashi Joh
Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan.

Chemoprevention strategies against gastric cancer (GC) need to be explored in light of the fact that stomach cancer still occurs in the absence of Helicobacter pylori (HP) infection and following HP eradication. We evaluated the effect of rebamipide on N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced carcinogenesis in SD rats. Thirty-nine male rats were divided into four groups based on whether or not they were treated with rebamipide and/or MNNG: Control, Rebamipide, Control-M, and Rebamipide-M groups. From 8 weeks of age, rats in the Control-M and Rebamipide-M groups received MNNG in drinking water for 30 weeks. The Rebamipide and Rebamipide-M groups were administered 5mg/kg/day of rebamipide. At 50 weeks, cancerous lesions were not observed in either the Control or Rebamipide groups. Nine rats in the Control-M group had developed GC, while four rats in the Rebamipide-M group had developed GC. The incidence of cancer in the Rebamipide-M group was significantly less than in the Control-M group (p<0.05), with a trend toward a lower incidence of invasive carcinoma in the Rebamipide-M group. Carcinomatous invasion into the muscularis propria was not observed in the Rebamipide-M group. In conclusion, the present study demonstrates that rebamipide suppresses. MNNG-induced carcinogenesis and may also inhibit progression of cancer in rats.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008297 Male Males
D008769 Methylnitronitrosoguanidine A nitrosoguanidine derivative with potent mutagenic and carcinogenic properties. Methylnitrosonitroguanidine,Nitrosomethylnitroguanidine,Nitrosonitromethylguanidine,MNNG,N-Methyl-N'-nitro-N-nitrosoguanidine,N Methyl N' nitro N nitrosoguanidine
D002273 Carcinogens Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. Carcinogen,Oncogen,Oncogens,Tumor Initiator,Tumor Initiators,Tumor Promoter,Tumor Promoters,Initiator, Tumor,Initiators, Tumor,Promoter, Tumor,Promoters, Tumor
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000409 Alanine A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM. Abufène,Alanine, L-Isomer,L-Alanine,Alanine, L Isomer,L Alanine,L-Isomer Alanine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000975 Antioxidants Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. Anti-Oxidant,Antioxidant,Antioxidant Activity,Endogenous Antioxidant,Endogenous Antioxidants,Anti-Oxidant Effect,Anti-Oxidant Effects,Anti-Oxidants,Antioxidant Effect,Antioxidant Effects,Activity, Antioxidant,Anti Oxidant,Anti Oxidant Effect,Anti Oxidant Effects,Anti Oxidants,Antioxidant, Endogenous,Antioxidants, Endogenous
D013274 Stomach Neoplasms Tumors or cancer of the STOMACH. Cancer of Stomach,Gastric Cancer,Gastric Neoplasms,Stomach Cancer,Cancer of the Stomach,Gastric Cancer, Familial Diffuse,Neoplasms, Gastric,Neoplasms, Stomach,Cancer, Gastric,Cancer, Stomach,Cancers, Gastric,Cancers, Stomach,Gastric Cancers,Gastric Neoplasm,Neoplasm, Gastric,Neoplasm, Stomach,Stomach Cancers,Stomach Neoplasm

Related Publications

Hironobu Tsukamoto, and Tsutomu Mizoshita, and Takahito Katano, and Noriyuki Hayashi, and Keiji Ozeki, and Masahide Ebi, and Takaya Shimura, and Yoshinori Mori, and Satoshi Tanida, and Hiromi Kataoka, and Tetsuya Tsukamoto, and Masae Tatematsu, and Takashi Joh
January 2008, Oncology reports,
Hironobu Tsukamoto, and Tsutomu Mizoshita, and Takahito Katano, and Noriyuki Hayashi, and Keiji Ozeki, and Masahide Ebi, and Takaya Shimura, and Yoshinori Mori, and Satoshi Tanida, and Hiromi Kataoka, and Tetsuya Tsukamoto, and Masae Tatematsu, and Takashi Joh
December 1991, The Tohoku journal of experimental medicine,
Hironobu Tsukamoto, and Tsutomu Mizoshita, and Takahito Katano, and Noriyuki Hayashi, and Keiji Ozeki, and Masahide Ebi, and Takaya Shimura, and Yoshinori Mori, and Satoshi Tanida, and Hiromi Kataoka, and Tetsuya Tsukamoto, and Masae Tatematsu, and Takashi Joh
September 1984, The Journal of surgical research,
Hironobu Tsukamoto, and Tsutomu Mizoshita, and Takahito Katano, and Noriyuki Hayashi, and Keiji Ozeki, and Masahide Ebi, and Takaya Shimura, and Yoshinori Mori, and Satoshi Tanida, and Hiromi Kataoka, and Tetsuya Tsukamoto, and Masae Tatematsu, and Takashi Joh
April 1976, Gan,
Hironobu Tsukamoto, and Tsutomu Mizoshita, and Takahito Katano, and Noriyuki Hayashi, and Keiji Ozeki, and Masahide Ebi, and Takaya Shimura, and Yoshinori Mori, and Satoshi Tanida, and Hiromi Kataoka, and Tetsuya Tsukamoto, and Masae Tatematsu, and Takashi Joh
December 1983, The science reports of the research institutes, Tohoku University. Ser. C, Medicine. Tohoku Daigaku,
Hironobu Tsukamoto, and Tsutomu Mizoshita, and Takahito Katano, and Noriyuki Hayashi, and Keiji Ozeki, and Masahide Ebi, and Takaya Shimura, and Yoshinori Mori, and Satoshi Tanida, and Hiromi Kataoka, and Tetsuya Tsukamoto, and Masae Tatematsu, and Takashi Joh
August 1989, Cancer research,
Hironobu Tsukamoto, and Tsutomu Mizoshita, and Takahito Katano, and Noriyuki Hayashi, and Keiji Ozeki, and Masahide Ebi, and Takaya Shimura, and Yoshinori Mori, and Satoshi Tanida, and Hiromi Kataoka, and Tetsuya Tsukamoto, and Masae Tatematsu, and Takashi Joh
December 1977, The Tohoku journal of experimental medicine,
Hironobu Tsukamoto, and Tsutomu Mizoshita, and Takahito Katano, and Noriyuki Hayashi, and Keiji Ozeki, and Masahide Ebi, and Takaya Shimura, and Yoshinori Mori, and Satoshi Tanida, and Hiromi Kataoka, and Tetsuya Tsukamoto, and Masae Tatematsu, and Takashi Joh
October 2008, Anti-cancer drugs,
Hironobu Tsukamoto, and Tsutomu Mizoshita, and Takahito Katano, and Noriyuki Hayashi, and Keiji Ozeki, and Masahide Ebi, and Takaya Shimura, and Yoshinori Mori, and Satoshi Tanida, and Hiromi Kataoka, and Tetsuya Tsukamoto, and Masae Tatematsu, and Takashi Joh
May 1980, European journal of cancer,
Hironobu Tsukamoto, and Tsutomu Mizoshita, and Takahito Katano, and Noriyuki Hayashi, and Keiji Ozeki, and Masahide Ebi, and Takaya Shimura, and Yoshinori Mori, and Satoshi Tanida, and Hiromi Kataoka, and Tetsuya Tsukamoto, and Masae Tatematsu, and Takashi Joh
April 1990, Cancer research,
Copied contents to your clipboard!